// Company Overview //
| Stock Name | 九源基因 |
|---|---|
| Stock Code | 02566 |
| Company Full Name | 九源基因 |
| Industry | 醫療保健 |
| Principal Activities | 公司是一家總部設于浙江省的中國生物制藥公司，擁有逾30年生物藥品及醫療器械研發、生產及商業化經驗。 |
| Listing Date | 2024-11-28 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | No data |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國浙江省杭州市錢塘區白楊街道8號大街23號 |
| Business Address (Hong Kong) | No data |
| Place of Incorporation | No data |
| Listing Method | No data |
| Listing Board | Main Board |
| Website | https://www.china-gene.com/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
// Offering Information //
| Offering Mechanism | 未知 |
|---|---|
| Clawback Tiers | No data |
| Prospectus Date | 2024-11-20 |
| Offer Price | HK$ 12.42 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 200 shares |
| Entry Threshold | HK$ 2,484 |
| Par Value | No data |
| Global Offering Shares | — |
| HK Public Offering Shares | — (0%) |
| International Placing Shares | — (0%) |
| Offer Ratio | No data |
| Total Shares Post-IPO | No data |
| Total Global Offering Size | HK$ — |
| Public Offering Size | HK$ — (0%) |
| Oversubscription Multiple | 675.8x |
| Valid Applications | 30,759 |
| Accepted Applications | — |
| Reallocation | No |
| Total Funds Raised | HK$ 281,926,548 |
| Greenshoe (Over-allotment Option) | No data |
// Valuation & Financials //
| Market Cap (at Offer Price) | HK$ 0 |
|---|---|
| Pre-IPO Valuation (Last Round) | No data |
| P/E Ratio | 23.21 |
| Profit/Loss Status | No data |
| Period-End Cash Balance | No data |
| Listing Expenses | ~HK$ 78,440,000 |
| Listing Expenses / Funds Raised | No data |
| Total Pre-IPO Investment | No data |
// First Day Performance
| First Day Close | Loading... |
|---|---|
| First Day Open | HK$ 7.5 |
| First Day Change | -38.41% |
| First Day Volume | 28954400.0 |
| First Day Turnover | 246224000.0 |
// Price Chart //
Loading...
// Use of Proceeds
| Use of Proceeds | 1、約40.0%（或187.3百萬港元）將分配至戰略性重點治療領域的選定在研產品的持續研發； 2、約30.0%（或140.4百萬港元）將用于現有及接近商業化產品的營銷及商業化； 3、約10.0%（或46.8百萬港元）將用于尋求戰略合作，以豐富在目標治療領域的產品組合； 4、約10.0%（或46.8百萬港元）將用于制造系統，以建設新生產線，并升級及進一步自動化現有生產設施，從而為產品的潛在需求增長及新產品的推出做好準備； 5、約10.0%（或46.8百萬港元）將用于為營運資金及其他一般企業用途提供資金。 |
|---|
// Underwriting Syndicate //
独家保荐人 (1)
华泰金融控股（香港）有限公司
整体协调人 (2)
华泰金融控股（香港）有限公司
中信里昂证券有限公司
联席账簿管理人 (5)
华泰金融控股（香港）有限公司
中信里昂证券有限公司
招银国际融资有限公司
瑞邦证券有限公司
百惠证券有限公司
联席牵头经办人 (5)
华泰金融控股（香港）有限公司
中信里昂证券有限公司
招银国际融资有限公司
瑞邦证券有限公司
百惠证券有限公司
// Cornerstone Investors //
Allotment Results Announcement
| # | Investor Name | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|
| 1 | 復星實業（香港）有限公司 | 2,505,000 | 2.30% | 1.02% | — | — |
| 2 | 香港健友實業有限公司 2025 | 2,505,000 | 2.30% | 1.02% | — | — |
| 3 | Delta Capital Hong Kong Limited | 772,800 | 0.71% | 0.31% | — | — |
// Directors & Management //
| Chairman | 傅航 |
|---|---|
| Company Secretary | 黃秀,何詠雅 |
No director data available.
// Major Shareholders //
| Major Shareholders & Holdings | 杭州中華東制藥有限公司(17.16%),杭州華升醫藥集團有限公司(13.24%),Corporacion Quimico-farmaceutica Esteve,Sociedad Anonima(12.22%),浙江網新科技創投有限公司(9.99%),Highland Pharma Limited(8.15%) |
|---|
// Allotment Benchmarks //
Pool A (Small Subscriptions)
| Shares Applied | Applicants | Allottees | Expected Lots |
|---|---|---|---|
| 200 | 5,458 | 5,458 | 0.20 |
| 400 | 1,459 | 1,459 | 0.22 |
| 600 | 2,009 | 2,009 | 0.24 |
| 800 | 592 | 592 | 0.27 |
| 1,000 | 914 | 914 | 0.29 |
| 1,200 | 282 | 282 | 0.31 |
| 1,400 | 217 | 217 | 0.36 |
| 1,600 | 269 | 269 | 0.41 |
| 1,800 | 141 | 141 | 0.45 |
| 2,000 | 1,125 | 1,125 | 0.50 |
| 3,000 | 964 | 964 | 0.75 |
| 4,000 | 628 | 628 | 1.00 |
| 5,000 | 317 | 317 | 1.12 |
| 6,000 | 252 | 252 | 1.32 |
| 7,000 | 756 | 756 | 1.50 |
| 8,000 | 307 | 307 | 1.68 |
| 9,000 | 140 | 140 | 1.84 |
| 10,000 | 1,378 | 1,378 | 2.00 |
| 20,000 | 2,109 | 2,109 | 2.30 |
| 30,000 | 1,674 | 1,674 | 2.33 |
| 40,000 | 2,389 | 2,389 | 3.00 |
| 50,000 | 385 | 385 | 3.25 |
| 60,000 | 342 | 342 | 3.45 |
| 70,000 | 242 | 242 | 3.99 |
| 80,000 | 296 | 296 | 4.08 |
| 90,000 | 169 | 169 | 4.54 |
| 100,000 | 767 | 767 | 5.00 |
| 150,000 | 523 | 523 | 6.00 |
| 200,000 | 556 | 556 | 7.00 |
| 250,000 | 280 | 280 | 8.00 |
| 300,000 | 315 | 315 | 9.00 |
| 350,000 | 959 | 959 | 9.97 |
| 400,000 | 978 | 978 | 13.40 |
Pool B (Large Subscriptions)
| Shares Applied | Applicants | Allottees | Expected Lots |
|---|---|---|---|
| 450,000 | 231 | 231 | 13.95 |
| 500,000 | 236 | 236 | 15.00 |
| 600,000 | 133 | 133 | 18.00 |
| 700,000 | 69 | 69 | 21.00 |
| 800,000 | 206 | 206 | 23.20 |
| 900,000 | 59 | 59 | 25.20 |
| 1,000,000 | 247 | 247 | 27.00 |
| 1,500,000 | 118 | 118 | 39.75 |
| 2,000,000 | 46 | 46 | 52.00 |
| 2,270,000 | 222 | 222 | 59.02 |
Allotment Benchmarks
